{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:11:19Z","timestamp":1790806279825,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T00:00:00Z","timestamp":1363564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T00:00:00Z","timestamp":1363564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sichuan Province Science and Technology Support Program of China","award":["2010FZ0046"],"award-info":[{"award-number":["2010FZ0046"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81100330"],"award-info":[{"award-number":["81100330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1111\/jcpt.12052","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T15:04:40Z","timestamp":1363619080000},"page":"249-253","source":"Crossref","is-referenced-by-count":12,"title":["Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-\u03b1 antagonist and cytokine profiling: a case-report and review of the literature"],"prefix":"10.1155","volume":"38","author":[{"given":"Yongkang","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine; West China Hospital; Sichuan University; Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Laboratory; West China Hospital; Sichuan University; Chengdu Sichuan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Laboratory; West China Hospital; Sichuan University; Chengdu Sichuan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Shuai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Laboratory; West China Hospital; Sichuan University; Chengdu Sichuan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Laboratory; West China Hospital; Sichuan University; Chengdu Sichuan Province China"},{"name":"Division of Molecular Bioregulation; Cancer Research Institute; Kanazawa University; Ishikawa Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,18]]},"reference":[{"key":"10.1111\/jcpt.12052-BIB0001|jcpt12052-cit-0001","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12052-BIB0002|jcpt12052-cit-0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","article-title":"The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12052-BIB0003|jcpt12052-cit-0003","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","article-title":"The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy","volume":"13","author":"Zhou","year":"2008","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12052-BIB0004|jcpt12052-cit-0004","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12052-BIB0005|jcpt12052-cit-0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jcpt.12052-BIB0006|jcpt12052-cit-0006","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12052-BIB0007|jcpt12052-cit-0007","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease","volume":"82","author":"Wagner","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1111\/jcpt.12052-BIB0008|jcpt12052-cit-0008","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3816\/CLM.2006.n.019","article-title":"Fatal interstitial pneumonitis related to rituximab-containing regimen","volume":"6","author":"Herishanu","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1111\/jcpt.12052-BIB0009|jcpt12052-cit-0009","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/jcpt.12052-BIB0010|jcpt12052-cit-0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: a systematic literature review","volume":"35","author":"Liote","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1111\/jcpt.12052-BIB0011|jcpt12052-cit-0011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12052-BIB0012|jcpt12052-cit-0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1111\/jcpt.12052-BIB0013|jcpt12052-cit-0013","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/jcpt.12052-BIB0014|jcpt12052-cit-0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12052-BIB0015|jcpt12052-cit-0015","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190127502","article-title":"Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis","volume":"42","author":"Kanelli","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/jcpt.12052-BIB0016|jcpt12052-cit-0016","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jcpt.12052-BIB0017|jcpt12052-cit-0017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/rheumatology\/kep015","article-title":"A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus","volume":"48","author":"Kishi","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12052-BIB0018|jcpt12052-cit-0018","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-011-1268-2","article-title":"Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma","volume":"90","author":"Huang","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1111\/jcpt.12052-BIB0019|jcpt12052-cit-0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12052-BIB0020|jcpt12052-cit-0020","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1111\/jcpt.12052-BIB0021|jcpt12052-cit-0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000338259","article-title":"Rituximab-induced interstitial pneumonia due to CD8-positive T cell infiltration","volume":"128","author":"Sato","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1111\/jcpt.12052-BIB0022|jcpt12052-cit-0022","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar2766","article-title":"Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients","volume":"11","author":"Schmidt","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/jcpt.12052-BIB0023|jcpt12052-cit-0023","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-3083.2008.02222.x","article-title":"Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases","volume":"69","author":"Vasakova","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1111\/jcpt.12052-BIB0024|jcpt12052-cit-0024","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000090248","article-title":"Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension","volume":"75","author":"Bargagli","year":"2008","journal-title":"Respiration"},{"key":"10.1111\/jcpt.12052-BIB0025|jcpt12052-cit-0025","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/1078-0432.CCR-07-1894","article-title":"Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12052-BIB0026|jcpt12052-cit-0026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.170.1.567","article-title":"Repression of bleomycin-induced pneumopathy by TNF","volume":"170","author":"Kuroki","year":"2003","journal-title":"J Immunol"},{"key":"10.1111\/jcpt.12052-BIB0027|jcpt12052-cit-0027","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy-rare but there!","volume":"50","author":"Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/jcpt.12052-BIB0028|jcpt12052-cit-0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(00)02430-2","article-title":"Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial","volume":"356","author":"Ronco","year":"2000","journal-title":"Lancet"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12052\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:52Z","timestamp":1671818692000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,18]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12052","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,18]]}}}